Non-Narcotic, Non-Addictive Treatment Options for Insomnia in a 69-Year-Old Woman
For this 69-year-old woman currently on zolpidem, the strongest evidence-based non-narcotic, non-addictive option is cognitive behavioral therapy for insomnia (CBT-I), which should be initiated as first-line treatment. 1 If pharmacologic therapy is needed, ramelteon (melatonin receptor agonist), low-dose doxepin, or dual orexin receptor antagonists (DORAs) are non-addictive alternatives. 1, 2
First-Line Treatment: Cognitive Behavioral Therapy for Insomnia (CBT-I)
The 2016 American College of Physicians guideline explicitly recommends CBT-I as the initial treatment for chronic insomnia in all adults, including older patients. 1 This is a multicomponent behavioral approach that includes:
- Stimulus control: Use bedroom only for sleep and sex; leave bedroom if unable to fall asleep within 15-20 minutes 2
- Sleep restriction: Limit time in bed to actual sleep time, then gradually increase
- Sleep hygiene education: Maintain consistent bed/wake times; avoid caffeine, nicotine, alcohol; no heavy exercise within 2 hours of bedtime 2
- Relaxation therapy: Progressive muscle relaxation, guided imagery, diaphragmatic breathing 2
- Cognitive therapy: Address misperceptions about sleep needs in aging
CBT-I has demonstrated sustained long-term benefits beyond medication alone and carries no risk of dependence or adverse effects. 2
Non-Addictive Pharmacologic Options
When behavioral therapy alone is insufficient, the following FDA-approved medications have no evidence of abuse potential or dependence:
Ramelteon (Melatonin Receptor Agonist)
- Mechanism: Acts on melatonin receptors involved in circadian rhythm regulation 2
- Key advantage: No significant effects indicative of abuse potential, motor impairment, or cognitive impairment 2
- Best for: Sleep-onset insomnia 3
- Elderly dosing: Start at lowest dose
Low-Dose Doxepin (3-6 mg)
- FDA-approved for insomnia at low doses 1
- Best for: Sleep maintenance problems 3
- Note: This is distinct from higher antidepressant doses; at low doses it acts as a histamine antagonist
Dual Orexin Receptor Antagonists (DORAs)
- Agents: Suvorexant, lemborexant, daridorexant 1, 4
- Mechanism: Inhibit wakefulness rather than induce sedation 4
- Key advantages: No evidence of rebound insomnia, withdrawal, or abuse potential 4
- Best for: Sleep maintenance 3
- Daridorexant: Newest agent with ideal 8-hour half-life and demonstrated 12-month efficacy 4
Critical Context: Zolpidem Concerns in Elderly
The patient's current medication (zolpidem 5 mg) is a benzodiazepine receptor agonist with significant concerns in elderly patients:
- Increased fall risk and injuries 5
- Potential increased mortality 5
- Next-day cognitive impairment documented in elderly 6
- Memory impairment (anterograde amnesia) at doses ≥10 mg 6
- FDA-approved only for short-term use (4-5 weeks) 6
- Rebound insomnia documented in elderly at doses >5 mg 6
Recommended Treatment Algorithm
Initiate CBT-I immediately as primary treatment 1
If pharmacologic therapy needed concurrently or CBT-I unavailable:
Gradual zolpidem discontinuation (if switching):
Options to Avoid
- Benzodiazepines: High risk of adverse effects in elderly, should not be used routinely 2, 3
- Antihistamines (diphenhydramine): Not recommended; anticholinergic effects problematic in elderly 3
- Trazodone: Despite common off-label use, carries significant risks and limited efficacy data 3
- Antipsychotics: Not recommended for insomnia 3